A newborn presents with liver damage and a urine succinylacetone test result greater than 600 umol/L. What does this indicate?

Prepare for the CAMLPR Chemistry Test. Enhance your understanding with interactive quizzes, flashcards, and detailed explanations. Boost your confidence and readiness for exam success!

Multiple Choice

A newborn presents with liver damage and a urine succinylacetone test result greater than 600 umol/L. What does this indicate?

A newborn with liver damage and a urine succinylacetone level this high points to tyrosinemia type I. In this condition, the enzyme fumarylacetoacetate hydrolase is deficient, causing a backup in tyrosine breakdown. One of the byproducts formed when the pathway backs up is succinylacetone, which is excreted in urine at very high levels and serves as a specific diagnostic marker for tyrosinemia type I. This explains the neonatal liver dysfunction observed. Understanding the context helps: tyrosinemia type I is treated differently from other metabolic disorders because the problem is in a specific step of tyrosine metabolism, not just a general buildup of phenylalanine or tyrosine. Early detection is important because therapy with nitisinone (NTBC) blocks an upstream step to prevent the formation of toxic metabolites, alongside dietary restriction of tyrosine and phenylalanine. So, the elevated urinary succinylacetone is a direct clue pointing to tyrosinemia type I rather than phenylalanine hydroxylase deficiency (PKU) or alkaptonuria.

A newborn with liver damage and a urine succinylacetone level this high points to tyrosinemia type I. In this condition, the enzyme fumarylacetoacetate hydrolase is deficient, causing a backup in tyrosine breakdown. One of the byproducts formed when the pathway backs up is succinylacetone, which is excreted in urine at very high levels and serves as a specific diagnostic marker for tyrosinemia type I. This explains the neonatal liver dysfunction observed.

Understanding the context helps: tyrosinemia type I is treated differently from other metabolic disorders because the problem is in a specific step of tyrosine metabolism, not just a general buildup of phenylalanine or tyrosine. Early detection is important because therapy with nitisinone (NTBC) blocks an upstream step to prevent the formation of toxic metabolites, alongside dietary restriction of tyrosine and phenylalanine.

So, the elevated urinary succinylacetone is a direct clue pointing to tyrosinemia type I rather than phenylalanine hydroxylase deficiency (PKU) or alkaptonuria.

More practice questions